Research programme: neurodegenerative disorders therapeutics - Medeia/Orion

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Medeia/Orion

Alternative Names: MDA-107; MDA-107X series

Latest Information Update: 02 Mar 2011

Price : $50

At a glance

  • Originator Medeia Therapeutics; Orion
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Neurodegenerative disorders

Most Recent Events

  • 02 Mar 2011 Preclinical development is ongoing in Finland
  • 22 Sep 2009 Preclinical development is ongoing in Finland
  • 19 Jun 2007 Preclinical trials in Neurodegenerative disorders in Finland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top